Lipid profile status and other related factors in patients with Hyperphenylalaninaemia

go back to reference Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376:1417–27.CrossRefPubMed Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376:1417–27.CrossRefPubMed

go back to reference Martínez-Pardo M, Marchante C, Dalmau J, Pérez M, Bellón C. Protocolo de diagnóstico, tratamiento y seguimiento de las hiperfenilalaninemias. An Esp Pediatr. 1998;114:3–18. Martínez-Pardo M, Marchante C, Dalmau J, Pérez M, Bellón C. Protocolo de diagnóstico, tratamiento y seguimiento de las hiperfenilalaninemias. An Esp Pediatr. 1998;114:3–18.

go back to reference Okano Y, Nagasaka H. Optimal serum phenylalanine for adult patients with phenylketonuria. Mol Genet Metab. 2013;110:424–30.CrossRefPubMed Okano Y, Nagasaka H. Optimal serum phenylalanine for adult patients with phenylketonuria. Mol Genet Metab. 2013;110:424–30.CrossRefPubMed

go back to reference Mirás A, Bóveda MD, Leis MR, Mera A, Aldámiz-Echevarría L, Fernández- Lorenzo JR, Fraga JM, Couce ML. Risk factors for developing mineral bone disease in phenylketonuric patients. Mol Genet Metab. 2013;108:149–54.CrossRefPubMed Mirás A, Bóveda MD, Leis MR, Mera A, Aldámiz-Echevarría L, Fernández- Lorenzo JR, Fraga JM, Couce ML. Risk factors for developing mineral bone disease in phenylketonuric patients. Mol Genet Metab. 2013;108:149–54.CrossRefPubMed

go back to reference Giovannini M, Verduci E, Salvatici E, Paci S, Riva E. Phenylketonuria: nutritional advances and challenges. Nutr Metab. 2012;9:1–7.CrossRef Giovannini M, Verduci E, Salvatici E, Paci S, Riva E. Phenylketonuria: nutritional advances and challenges. Nutr Metab. 2012;9:1–7.CrossRef

go back to reference Huemer M, Simma B, Mayr D, Möslinger D, Mühl A, Schmid I, Ulmer H, Bodamer OA. Free asymmetric dimethylarginine (ADMA) is low in children and adolescent with classical PKU. J Inherit Metab Dis. 2012;35:817–21.CrossRefPubMed Huemer M, Simma B, Mayr D, Möslinger D, Mühl A, Schmid I, Ulmer H, Bodamer OA. Free asymmetric dimethylarginine (ADMA) is low in children and adolescent with classical PKU. J Inherit Metab Dis. 2012;35:817–21.CrossRefPubMed

go back to reference Crujeiras V, Aldámiz-Echevarría L, Dalmau J, Vitoria I, Andrade F, Roca I, Leis R, Fernandez-Marmiesse A, Couce ML. Vitamin and mineral status in patients with hyperphenylalaninemia. Mol Genet Metab. 2015;115(4):145–50.CrossRefPubMed Crujeiras V, Aldámiz-Echevarría L, Dalmau J, Vitoria I, Andrade F, Roca I, Leis R, Fernandez-Marmiesse A, Couce ML. Vitamin and mineral status in patients with hyperphenylalaninemia. Mol Genet Metab. 2015;115(4):145–50.CrossRefPubMed

go back to reference Evans S, Daly A, MacDonald J, Preece MA, Santra S, Vijay S, Chakrapani A, MacDonald A. The micronutrient status of patients with phenylketonuria on dietary treatment: an ongoing challenge. Ann Nutr Metab. 2014;65(1):42–8.CrossRefPubMed Evans S, Daly A, MacDonald J, Preece MA, Santra S, Vijay S, Chakrapani A, MacDonald A. The micronutrient status of patients with phenylketonuria on dietary treatment: an ongoing challenge. Ann Nutr Metab. 2014;65(1):42–8.CrossRefPubMed

go back to reference Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A, Dokoupil K, GokmenOzel H, Lammardo AM, Goyens P, Feillet F. Micronutrient status in phenylketonuria. Mol Genet Metab. 2013;110(Suppl):S6–17.CrossRefPubMed Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A, Dokoupil K, GokmenOzel H, Lammardo AM, Goyens P, Feillet F. Micronutrient status in phenylketonuria. Mol Genet Metab. 2013;110(Suppl):S6–17.CrossRefPubMed

go back to reference Lammardo AM, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A, Dokoupil K, Ozel HG, Goyens P, Feillet F. Main issues in micronutrient supplementation in phenylketonuria. Mol Genet Metab. 2013;110(Suppl):S1–5.CrossRefPubMed Lammardo AM, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A, Dokoupil K, Ozel HG, Goyens P, Feillet F. Main issues in micronutrient supplementation in phenylketonuria. Mol Genet Metab. 2013;110(Suppl):S1–5.CrossRefPubMed

go back to reference Rohde C, von Teeffelen-Heithoff A, Thiele AG, Arelin M, Mütze U, Kiener C, Gerloff J, Baerwald C, Schultz S, Heller C, Müller AS, Kiess W, Beblo S. PKU patients on a relaxed diet may be at risk for micronutrient deficiencies. Eur J ClinNutr. 2014;68:119–24.CrossRef Rohde C, von Teeffelen-Heithoff A, Thiele AG, Arelin M, Mütze U, Kiener C, Gerloff J, Baerwald C, Schultz S, Heller C, Müller AS, Kiess W, Beblo S. PKU patients on a relaxed diet may be at risk for micronutrient deficiencies. Eur J ClinNutr. 2014;68:119–24.CrossRef

go back to reference Schulpis KH, KarakonstantakisbT BA, Karikasc GA, Papassotiriou I. The association of serum lipids, lipoproteins and apolipoproteins with selected trace elements and minerals in phenylketonuric patients on diet. ClinNutr. 2004;23:401–7. Schulpis KH, KarakonstantakisbT BA, Karikasc GA, Papassotiriou I. The association of serum lipids, lipoproteins and apolipoproteins with selected trace elements and minerals in phenylketonuric patients on diet. ClinNutr. 2004;23:401–7.

go back to reference LaVoie SM, Harding CO, Gillingham MB. Normal fatty acids concentrations in young children with phenylketonuria (PKU). Top Clin Nutr. 2009;24:333–40.CrossRefPubMedPubMedCentral LaVoie SM, Harding CO, Gillingham MB. Normal fatty acids concentrations in young children with phenylketonuria (PKU). Top Clin Nutr. 2009;24:333–40.CrossRefPubMedPubMedCentral

go back to reference Verduci E, Agostoni C, Biondi ML, Radaelli G, Giovannini M, Riva E. Apolipoprotein B gene polimorphism and plasma lipid levels in phenylketonuric children. Prostaglandins LeukotEssent Fatty Acids. 2004;71:117–20.CrossRef Verduci E, Agostoni C, Biondi ML, Radaelli G, Giovannini M, Riva E. Apolipoprotein B gene polimorphism and plasma lipid levels in phenylketonuric children. Prostaglandins LeukotEssent Fatty Acids. 2004;71:117–20.CrossRef

go back to reference Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, Bodamer OA, Brosco JP, Brown CS, Burlina AB, Burton BK, Chang CS, Coates PM, Cunningham AC, Dobrowolski SF, Ferguson JH, Franklin TD, Frazier DM, Grange DK, Greene CL, Groft SC, Harding CO, Howell RR, Huntington KL, Hyatt-Knorr HD, Jevaji IP, Levy HL, Lichter-Konecki U, Lindegren ML, Lloyd-Puryear MA, Matalon K, MacDonald A, McPheeters ML, Mitchell JJ, Mofidi S, Moseley KD, Mueller CM, Mulberg AE, Nerurkar LS, Ogata BN, Pariser AR, Prasad S, Pridjian G, Rasmussen SA, Reddy UM, Rohr FJ, Singh RH, Sirrs SM, Stremer SE, Tagle DA, Thompson SM, Urv TK, Utz JR, van Spronsen F, Vockley J, Waisbren SE, Weglicki LS, White DA, Whitley CB, Wilfond BS, Yannicelli S, Young JM. Phenylketonuria Scientific Review Conference: state of the science and future research needs. Mol Genet Metab. 2014;112:87–122.CrossRefPubMed Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, Bodamer OA, Brosco JP, Brown CS, Burlina AB, Burton BK, Chang CS, Coates PM, Cunningham AC, Dobrowolski SF, Ferguson JH, Franklin TD, Frazier DM, Grange DK, Greene CL, Groft SC, Harding CO, Howell RR, Huntington KL, Hyatt-Knorr HD, Jevaji IP, Levy HL, Lichter-Konecki U, Lindegren ML, Lloyd-Puryear MA, Matalon K, MacDonald A, McPheeters ML, Mitchell JJ, Mofidi S, Moseley KD, Mueller CM, Mulberg AE, Nerurkar LS, Ogata BN, Pariser AR, Prasad S, Pridjian G, Rasmussen SA, Reddy UM, Rohr FJ, Singh RH, Sirrs SM, Stremer SE, Tagle DA, Thompson SM, Urv TK, Utz JR, van Spronsen F, Vockley J, Waisbren SE, Weglicki LS, White DA, Whitley CB, Wilfond BS, Yannicelli S, Young JM. Phenylketonuria Scientific Review Conference: state of the science and future research needs. Mol Genet Metab. 2014;112:87–122.CrossRefPubMed

go back to reference National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. National Heart, Lung and Blood Institute, Bethesda, Maryland. Pediatrics. 2004;114:555–6.CrossRef National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. National Heart, Lung and Blood Institute, Bethesda, Maryland. Pediatrics. 2004;114:555–6.CrossRef

go back to reference The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens. 2013;31:1281–357.CrossRef The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens. 2013;31:1281–357.CrossRef

go back to reference Acosta PB, Yannicelli SY, R. Singh R, Mofidi S, Steiner R, De Vincentis E, Jurecki E, Bernstein L, Gleason S, Chetty M, Rouse B. Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J Am Diet Assoc. 2003;103:1167–73.CrossRefPubMed Acosta PB, Yannicelli SY, R. Singh R, Mofidi S, Steiner R, De Vincentis E, Jurecki E, Bernstein L, Gleason S, Chetty M, Rouse B. Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J Am Diet Assoc. 2003;103:1167–73.CrossRefPubMed

go back to reference WHO, Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1–452. WHO, Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1–452.

go back to reference WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr. 2006;450:S76–85. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr. 2006;450:S76–85.

go back to reference Tojo Sierra R, Leis Trabazo R. Estudio Galinut. Valores Estandar de Galicia. Santiago de Compostela: Universidad de Santiago de Compostela; 1999. Tojo Sierra R, Leis Trabazo R. Estudio Galinut. Valores Estandar de Galicia. Santiago de Compostela: Universidad de Santiago de Compostela; 1999.

go back to reference Zimmet P, Alberti G, Shaw J. Nueva definición mundial de la IDF del Síndrome metabólico. Diabetes Voice. 2005;50:31–3. Zimmet P, Alberti G, Shaw J. Nueva definición mundial de la IDF del Síndrome metabólico. Diabetes Voice. 2005;50:31–3.

go back to reference Frisancho R. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J ClinNutr. 1981;34:2540–5. Frisancho R. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J ClinNutr. 1981;34:2540–5.

go back to reference R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2015. https://www.R-project.org/. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2015. https://​www.​R-project.​org/​.

go back to reference Schulpi KH, Scarpalezou A. Triglycerides, cholesterol HDL, LDL, and VLDL cholesterol in serum of phenylketonuric children under dietary control. Clin Pediatr. 1989;28:466–9.CrossRef Schulpi KH, Scarpalezou A. Triglycerides, cholesterol HDL, LDL, and VLDL cholesterol in serum of phenylketonuric children under dietary control. Clin Pediatr. 1989;28:466–9.CrossRef

go back to reference Colome C, Artuch R, Lambruschini N, Cambra FJ, Campistol J, Vilaseca MA. Is there a relationship between plasma phenylalanine and cholesterol in phenylketonuric patients under dietary treatment? Clin Biochem. 2001;33:373–6.CrossRef Colome C, Artuch R, Lambruschini N, Cambra FJ, Campistol J, Vilaseca MA. Is there a relationship between plasma phenylalanine and cholesterol in phenylketonuric patients under dietary treatment? Clin Biochem. 2001;33:373–6.CrossRef

go back to reference Giovannini M, Agostoni C, Bellu R, Ghiglioni D, Giuffre B, Biasucci G, Riva E. Nutritional aspects of phenylketonuria: correlation between blood lipids and immunoglobulins G, A and M in a phenylketonuric paediatric population on diet therapy. Dev Brain Dysfunct. 1993;6:168–71. Giovannini M, Agostoni C, Bellu R, Ghiglioni D, Giuffre B, Biasucci G, Riva E. Nutritional aspects of phenylketonuria: correlation between blood lipids and immunoglobulins G, A and M in a phenylketonuric paediatric population on diet therapy. Dev Brain Dysfunct. 1993;6:168–71.

go back to reference Verduci E, Banderali G, Moretti F, Lassandro C, Cefalo G, Radaelli G, Salvatici E, Giovannini M. Diet in children with phenylketonuria and risk of cardiovascular disease: A narrative overview. Nutr Metab Cardiovasc Dis. 2016;26:171–7. Verduci E, Banderali G, Moretti F, Lassandro C, Cefalo G, Radaelli G, Salvatici E, Giovannini M. Diet in children with phenylketonuria and risk of cardiovascular disease: A narrative overview. Nutr Metab Cardiovasc Dis. 2016;26:171–7.

go back to reference Castillo M, Zafra MF, García-Peregrin E. Inhibition of brain and liver 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental hyperphenylalaninemia. Neurochem Res. 1988;13:551–5.CrossRefPubMed Castillo M, Zafra MF, García-Peregrin E. Inhibition of brain and liver 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental hyperphenylalaninemia. Neurochem Res. 1988;13:551–5.CrossRefPubMed

go back to reference Darnton-Hill I, Nishida C, James WPT. A life course approach to diet, nutrition and the prevention of chronic diseases. Public Health Nutr. 2004;7:101–21.CrossRefPubMed Darnton-Hill I, Nishida C, James WPT. A life course approach to diet, nutrition and the prevention of chronic diseases. Public Health Nutr. 2004;7:101–21.CrossRefPubMed

go back to reference Rocha JC, van Spronsen FJ, Almeida MF, Soares G, Quelhas D, Ramos E, Guimarães JT, Borges N. Dietary treatment in phenylketonuria does not lead to increased risk of obesity or metabolic syndrome. Mol Genet Metab. 2012;107:659–63.CrossRefPubMed Rocha JC, van Spronsen FJ, Almeida MF, Soares G, Quelhas D, Ramos E, Guimarães JT, Borges N. Dietary treatment in phenylketonuria does not lead to increased risk of obesity or metabolic syndrome. Mol Genet Metab. 2012;107:659–63.CrossRefPubMed

go back to reference Aldámiz-Echevarría L, Bueno MA, Couce ML, Lage S, Dalmau J, Vitoria I, Andrade F, Blasco J, Alcalde C, Gil D, García MC, González-Lamuño D, Ruiz M, Peña-Quintana L, Ruiz MA, González D, Sánchez-Valverde F. Anthropometric characteristics and nutrition in a cohort of PAH-deficient patients. Clin Nutr. 2014;33:702–17.CrossRefPubMed Aldámiz-Echevarría L, Bueno MA, Couce ML, Lage S, Dalmau J, Vitoria I, Andrade F, Blasco J, Alcalde C, Gil D, García MC, González-Lamuño D, Ruiz M, Peña-Quintana L, Ruiz MA, González D, Sánchez-Valverde F. Anthropometric characteristics and nutrition in a cohort of PAH-deficient patients. Clin Nutr. 2014;33:702–17.CrossRefPubMed

go back to reference Campos H, Genest J, Blijlevens E, Mc Namara JR, Jenner JL, Ordovas JM. Low density lipoprotein size and coronary artery disease. Arterioscler Thromb. 1992;12:187–95.CrossRefPubMed Campos H, Genest J, Blijlevens E, Mc Namara JR, Jenner JL, Ordovas JM. Low density lipoprotein size and coronary artery disease. Arterioscler Thromb. 1992;12:187–95.CrossRefPubMed

go back to reference Reunanen A, Knekt P, Marniemi J, Maki J, Maatela J, Aromaa A. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. Eur J Clin Nutr. 1996;50:431–7.PubMed Reunanen A, Knekt P, Marniemi J, Maki J, Maatela J, Aromaa A. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. Eur J Clin Nutr. 1996;50:431–7.PubMed

go back to reference Yount NY, Mc Namara DJ, Al Ohtman AA, Lei KY. The effect of copper deficiency on rat hepatic 3-hydroxy-3-methylglutaryl co-enzyme. A reductase activity. J Nutr Biochem. 1990;1:27–33.CrossRef Yount NY, Mc Namara DJ, Al Ohtman AA, Lei KY. The effect of copper deficiency on rat hepatic 3-hydroxy-3-methylglutaryl co-enzyme. A reductase activity. J Nutr Biochem. 1990;1:27–33.CrossRef

go back to reference Schulpis KH, Karikas GA, Papakonstantinou ED. Homocysteine and other vascular risk factors in patients with phenylketonuria on diet. Acta Paediatr. 2002;91:1–5.CrossRef Schulpis KH, Karikas GA, Papakonstantinou ED. Homocysteine and other vascular risk factors in patients with phenylketonuria on diet. Acta Paediatr. 2002;91:1–5.CrossRef

go back to reference Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of c‐reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–65.CrossRefPubMed Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of c‐reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–65.CrossRefPubMed

go back to reference Dokoupil K, Gokmen-Ozel H, Lammardo AM, Motzfeldt K, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A. Optimising growth in phenylketonuria: current state of the clinical evidence base. Clin Nutr. 2012;31:16–21.CrossRefPubMed Dokoupil K, Gokmen-Ozel H, Lammardo AM, Motzfeldt K, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A. Optimising growth in phenylketonuria: current state of the clinical evidence base. Clin Nutr. 2012;31:16–21.CrossRefPubMed

go back to reference Giovannini M, Verduci E, Salvatici E, Fiori L, Riva E. Phenylketonuria: dietary and therapeutic challenges. J Inherit Metab Dis. 2006;30:145–52.CrossRef Giovannini M, Verduci E, Salvatici E, Fiori L, Riva E. Phenylketonuria: dietary and therapeutic challenges. J Inherit Metab Dis. 2006;30:145–52.CrossRef

go back to reference Scaglioni S, Verduci E, Fiori L, Lammardo AM, Rossi S, Radaelli G, Riva E, Giovannini M. Body mass index rebound and overweight at 8 years of age in hyperphenylalaninaemic children. Acta Paediatr. 2004;93:1596–600.CrossRefPubMed Scaglioni S, Verduci E, Fiori L, Lammardo AM, Rossi S, Radaelli G, Riva E, Giovannini M. Body mass index rebound and overweight at 8 years of age in hyperphenylalaninaemic children. Acta Paediatr. 2004;93:1596–600.CrossRefPubMed

go back to reference Overweight and obesity and their impact on health. Global Status Report on noncommunicable diseases 2014. World Health Organization (WHO). http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf. Overweight and obesity and their impact on health. Global Status Report on noncommunicable diseases 2014. World Health Organization (WHO). http://​apps.​who.​int/​iris/​bitstream/​10665/​148114/​1/​9789241564854_​eng.​pdf.

go back to reference Mazzola PN, Nalin T, Castro K, van Rijn M, Derks TG, Perry ID, Mainieri AS, Schwartz IV. Analysis of body composition and nutritional status in Brazilian phenylketonuria patients. Mol Genet Metab Rep. 2016;6:16–20.CrossRefPubMedPubMedCentral Mazzola PN, Nalin T, Castro K, van Rijn M, Derks TG, Perry ID, Mainieri AS, Schwartz IV. Analysis of body composition and nutritional status in Brazilian phenylketonuria patients. Mol Genet Metab Rep. 2016;6:16–20.CrossRefPubMedPubMedCentral